Glenmede Trust CO Na Arrowhead Pharmaceuticals, Inc. Transaction History

Glenmede Trust CO Na

$20.6 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$21.2 - $31.03 $15,158 - $22,186	-715 Reduced 4.23%	16,190 $495,000
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $180,151 - $248,086	6,876 Added 68.56%	16,905 $454,000
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $133,413 - $216,965	-5,634 Reduced 35.97%	10,029 $254,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $5,628 - $8,152	201 Added 1.3%	15,663 $635,000
Q3 2022 Nov 16, 2022	BUY	$29.63 - $48.31 $161,631 - $263,531	5,455 Added 54.51%	15,462 $510,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $435 - $769	-11 Reduced 0.11%	10,007 $459,000
Q4 2021 Feb 15, 2022	BUY	$58.09 - $82.51 $638 - $907	11 Added 0.11%	10,018 $664,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $1,809 - $2,633	-31 Reduced 0.31%	10,007 $624,000
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $1,926 - $2,799	31 Added 0.31%	10,038 $831,000
Q1 2021 May 18, 2021	SELL	$61.35 - $90.47 $674 - $995	-11 Reduced 0.11%	10,007 $663,000
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $788 - $1,536	18 Added 0.18%	10,018 $768,000
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $929 - $1,435	-28 Reduced 0.28%	10,000 $430,000
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $17,474 - $28,947	-669 Reduced 6.25%	10,028 $432,000
Q4 2019 Feb 12, 2020	BUY	$28.14 - $73.01 $1,519 - $3,942	54 Added 0.51%	10,697 $678,000
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $9,873 - $13,107	376 Added 3.66%	10,643 $299,000
Q2 2019 Aug 13, 2019	BUY	$17.43 - $28.82 $4,653 - $7,694	267 Added 2.67%	10,267 $272,000
Q4 2017 Feb 15, 2018	BUY	$3.14 - $4.5 $15,700 - $22,500	5,000 Added 100.0%	10,000 $36,000
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $8,450 - $21,650	5,000	5,000 $0

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.

Account